Réactions cutanéomuqueuses au cours d’un suivi prospectif systématique d’une cohorte de 48 patients traités par télaprévir pour une hépatite C
S. Lorcy(Inserm), C. Gaudy, Jean‐Jacques Grob(Aix-Marseille Université), Daniele Botta(University of Geneva), Isabelle Portal(Hôpital de la Conception), Martín Richard(Hôpital de la Timone)
Cited by 0
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
|New England Journal of Medicine|2019|1.4k
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
|New England Journal of Medicine|2016|1.3k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k